Your rationale for selling out in the pump is based on:- Low...

Your rationale for selling out in the pump is based on:

- Low half life and diminished efficacy
- Problems with accessibility to the drug
- Historical precedence for this class of drugs failing
- Myriad of other reasons which are specious

And yet you say Phase 2 will succeed?

You've given us every reason for why Argenica won't succeed or for the headwinds they'll face in getting the drug to market. You haven't proffered any substantial reason why the drug might succeed.

In response to the above list:

It will be up to the physician how much of the drug is administered, the only issue is diminishing returns in increasing dosage. Keeping a liquid form in appropriate storage at a given hospital is an extremely simple exercise, technical challenges may present if they want to impart mobility to the drug for use with first responders. But as discussed already that is not hard to overcome. Clinuvel's peptide afamelanotide is currently being worked into two main formulations in addition to the already approved implant: Prenumbra Instant and Prenumbra Modified Release. Instant will be used for stroke for immediate treatment, this formulation will give physicians dosing options ie the stroke insult is more serious than first indicated requiring elevated dosing. Modified Release is expected to be used in stroke also once the patient is stabilised but in addition it's expected the drug might assist with managing multiple sclerosis symptoms. The company has mentioned "rheology" a number of times so clearly they are looking at the flow and release characteristics of their formulations to enable both mobility and managed drug release.

Last year a study was conducted by researchers from Taiwan using afamelanotide (I don't believe this was done in conjunction with Clinuvel) whereby they compared a gel they made with afamelanotide to liquid afamelanotide. They tested the drugs on frogs, and the gel was able to induce and maintain melanin production for a month compared with the liquid afamelanotide which only lasted a matter of hours. This is exactly what Clinvuel is working on feverishly in their R&D lab in Singapore, they haven't released any results from their endeavours yet these researchers from Taiwan went ahead and did it like a high school project lol. The point of this is there is movement in the technological space around peptides and I don't accept that based on historical precedence they're going to have a problem. Its a time issue not a fundamental chemistry problem.

So, I have no issues with accessibility and half life of the drug. If the drug is safe, an attending physician may very well decide to constantly bathe the brain in ARG-007. Clinuvel administered something like 4 implants of afamelanotide over 7 days to maintain elevated levels of the drug as the stroke patient proceeded through their condition. It can be done.